An interventional study of Video-Guided Physical Activity Program in Overweight and Obesity, sponsored by Guangzhou University. Completed at 1 site in China. Open to participants aged 9 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Guangzhou University · Not applicable, Interventional, and Treatment
Among 597 studies in Obesity with a site in China — 220 open to participants now, 282 under way, 68 of them phase 3. Obesity · China.
Among the 597 studies in Obesity with a site in China, this one is the 280th largest by enrollment of the 499 interventional ones that give a count, is one of 41 that started in 2022, is one of 211 with no phase, and was the 569th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
Browse Obesity studies →220 of the 597 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 9 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
597 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 100 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 41 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Median enrollment 120 across the 499 interventional studies, 310 across the 98 observational. Of the 238 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
238 of 597 have an industry lead sponsor. The 10 most frequent:
Guangzhou University is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Guangzhou University has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
101 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Among the 597 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled study evaluated the effects of a 4-week Brain Breaks® exercise video intervention on physical activity and Transtheoretical Model-related psychosocial factors among overweight and obese children and adolescents in China. Participants were randomly assigned to an intervention group or a control group. The intervention group participated in short, video-based physical activity sessions during school breaks, while the control group did not receive the Brain Breaks intervention. Outcomes included physical activity participation, stage of exercise behavior change, exercise self-efficacy, perceived benefits of exercise, and perceived barriers to exercise.
This study was conducted to examine whether a school-based Brain Breaks® exercise video intervention could improve physical activity and psychosocial determinants of exercise behavior among overweight and obese children and adolescents in China. The intervention was informed by the Transtheoretical Model, which conceptualizes exercise behavior as progressing through different stages of behavioral change.
Eligible participants were randomly assigned to an intervention group or a control group. Participants in the intervention group received a 4-week Brain Breaks® exercise video program during school breaks. The program consisted of approximately 10 minutes of moderate-to-high-intensity video-guided physical activity per day. Participants followed short exercise video segments designed to encourage movement and participation in physical activity. Participants in the control group did not receive the Brain Breaks intervention during the study period.
Assessments were conducted before and after the intervention. The study evaluated physical activity participation and several Transtheoretical Model-related psychosocial constructs, including stage of exercise behavior change, exercise self-efficacy, perceived benefits of exercise, and perceived barriers to exercise. The study was designed to determine whether changes in these outcomes differed between the intervention and control groups following the 4-week intervention.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's enrollment of 100 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →Guangzhou University is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm received a 4-week Brain Breaks® exercise video intervention. The intervention consisted of approximately 10 minutes of moderate-to-high-intensity video-guided physical activity during school breaks each day. Participants followed short exercise video segments designed to increase physical activity and support exercise behavior change.
Behavioral: Video-Guided Physical Activity Program
Participants in this arm did not receive the Brain Breaks® exercise video intervention during the study period and continued their usual school activities.
Participants assigned to the intervention group received a 4-week video-guided physical activity program using Brain Breaks exercise videos. The intervention consisted of approximately 10 minutes of moderate-to-high-intensity physical activity during school breaks each day. Participants followed short exercise video segments designed to increase physical activity participation and support exercise behavior change. The intervention was delivered in the school setting during the study period.
Change in Total Physical Activity Measured by the Chinese Version of the International Physical Activity Questionnaire
Physical activity was assessed using the 7-item Chinese version of the International Physical Activity Questionnaire (IPAQ-C), which assesses physical activity intensity and sitting time during the previous 7 days. Total physical activity was expressed as metabolic equivalent task minutes per week (MET-min/week). Higher values indicate a greater amount of physical activity. Change from baseline to Week 4 was evaluated between the intervention and control groups.
Time frame: Baseline and Week 4
Change in Stage of Exercise Behavior Change
Stage of exercise behavior change was assessed according to the Transtheoretical Model. Participants were classified into one of five stages: precontemplation, contemplation, preparation, action, or maintenance. Changes in stage of exercise behavior from baseline to the end of the 4-week intervention were evaluated between groups.
Time frame: Baseline and Week 4
Change in Exercise Self-Efficacy Measured by the Chinese Version of the Exercise Self-Efficacy Scale
xercise self-efficacy was assessed using the 18-item Chinese version of the Exercise Self-Efficacy Scale. Each item is rated on a 5-point Likert scale from 1 (not at all confident) to 5 (completely confident). The mean score ranges from 1 to 5, with higher scores indicating greater exercise self-efficacy. Change from baseline to Week 4 was evaluated between the intervention and control groups.
Time frame: Baseline and Week 4
Change in Perceived Benefits of Exercise Measured by the Chinese Version of the Decisional Balance Scale
Perceived benefits of exercise were assessed using the Benefits subscale of the 10-item Chinese version of the Decisional Balance Scale. The Benefits subscale consists of 5 items rated on a 5-point scale. The mean subscale score ranges from 1 to 5, with higher scores indicating greater perceived benefits of exercise. Change from baseline to Week 4 was evaluated between the intervention and control groups.
Time frame: Baseline and Week 4
Change in Perceived Barriers to Exercise Measured by the Chinese Version of the Decisional Balance Scale
Perceived barriers to exercise were assessed using the Barriers subscale of the 10-item Chinese version of the Decisional Balance Scale. The Barriers subscale consists of 5 items rated on a 5-point scale. The mean subscale score ranges from 1 to 5, with higher scores indicating greater perceived barriers to exercise and therefore a less favorable outcome. Change from baseline to Week 4 was evaluated between the intervention and control groups.
Time frame: Baseline and Week 4
Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in the publication will be shared. The shared data may include participant-level demographic information, physical activity measures, and Transtheoretical Model-related psychosocial measures. A data dictionary will also be made available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning within 6 months after publication of the study results. The duration of data availability has not been prespecified.
Access criteria: Access will be considered for qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators. Data will be shared only for approved research purposes and after appropriate data-use conditions have been agreed upon. Only de-identified data will be provided.
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jun 2022, 0 months.
Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 0 months is below that.
Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.